Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids

CD248 and integrin alpha-8 are candidate markers for differentiating lung fibroblast subtypes

(2020) Sayomi Matsushima et al.   BMC Pulmonary Medicine

Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology

(2019) Meagan Myers et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Patient-specific tumor growth trajectories determine persistent and resistant cancer cell populations during treatment with targeted therapies

(2019) Clemens Grassberger et al.   CANCER RESEARCH

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer

(2019) Peter T Harrison et al.   SEMINARS IN CANCER BIOLOGY

RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies

(2019) Ioanna Giopanou et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period–The IMPACT study.

(2018) Apostolia Maria Tsimberidou et al.   JOURNAL OF CLINICAL ONCOLOGY

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

(2018) Isamu Okamoto et al.   LUNG CANCER

Multiclonal tumor origin: Evidence and implications

(2018) Barbara L. Parsons   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations

(2018) Jesse J. Salk et al.   NATURE REVIEWS GENETICS

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

(2018) Georgios Vlachogiannis et al.   SCIENCE

Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance

(2018) Peter T. Harrison et al.   Essays in Biochemistry

Retaining Cell-Cell Contact Enables Preparation and Culture of Spheroids Composed of Pure Primary Cancer Cells From Colorectal Cancer

(2018) Jumpei Kondo et al.   GASTROENTEROLOGY

Bioengineering-inspired three-dimensional culture systems: Organoids to create tumor microenvironment

(2018) Pelin Saglam-Metiner et al.   GENE

Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas

(2017) Barbara L. Parsons et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

Chemotherapeutics-resistance “arms” race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer

(2017) Pankaj Kumar Singh et al.   LIFE SCIENCES

Combination therapy in combating cancer

(2017) Reza Bayat Mokhtari et al.   Oncotarget

Modeling Development and Disease with Organoids

(2016) Hans Clevers   CELL

Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma

(2016) Deborah A. Belchis et al.   Oncotarget

Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas

(2016) Meagan B. Myers et al.   NEOPLASIA

The influence of subclonal resistance mutations on targeted cancer therapy

(2015) Michael W. Schmitt et al.   Nature Reviews Clinical Oncology

Low-frequencyKRASmutations are prevalent in lung adenocarcinomas

(2015) Meagan B Myers et al.   Personalized Medicine

Organoid modeling for cancer precision medicine

(2015) Michael A Cantrell et al.   Genome Medicine

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

(2015) James Andrew McCubrey et al.   Oncotarget

Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation

(2013) Hiroko Endo et al.   Journal of Thoracic Oncology

KRASmutant tumor subpopulations can subvert durable responses to personalized cancer treatments

(2013) Barbara L Parsons et al.   Personalized Medicine

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

(2012) Sandra Misale et al.   NATURE

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

(2012) Luis A. Diaz Jr et al.   NATURE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

ACB-PCR Quantification of K-RASCodon 12 GAT and GTT Mutant Fraction in Colon Tumor and Non-Tumor Tissue

(2010) Barbara L. Parsons et al.   CANCER INVESTIGATION

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE